Alzheimer Disease Clinical Trial
Official title:
DC Longitudinal Study on Aging and Specimen Bank
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is
conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's
disease, mild cognitive impairment and other neurodegenerative diseases. Further, this study
is assessing longitudinal changes in biological, lifestyle, and cognitive assessment
collection.
The primary goal of this study is to examine the feasibility of biochemical assays, genetic
testing, and cognitive and lifestyle assessments in the ante-mortem diagnosis of Alzheimer's
disease, mild cognitive impairment and other neurodegenerative diseases. This research
involves genetic and cognitive status testing but the findings will not be shared with
research subjects. This will be accomplished ex vivo using blood, and/or cerebrospinal fluid
(CSF) specimens from patients with a diagnosis of probable Alzheimer's disease, mild
cognitive impairment, or other neurodegenerative diseases and from normal controls.
These studies will examine the feasibility of using various biochemical assays in blood,
and/or cerebrospinal fluid, genetic testing, cognitive status assessments, and lifestyle
questionnaires to aid in the ante-mortem diagnosis of Alzheimer's and other neurodegenerative
diseases.
Subjects have 2 options for participation. They may solely participate in the main study or
the main study and the longitudinal substudy. The main study includes a single visit at which
demographic and medical information will be recorded, brief cognitive testing, and blood
and/or cerebrospinal fluid (CSF)(optional) specimens will be collected for the research
assays. Genetic testing will take place. No clinical laboratory testing will be done and no
results will be communicated to subjects.
During the Longitudinal substudy, each subject will be asked to participate in ongoing
longitudinal study visits at which demographic and medical information will be recorded,
cognitive testing and lifestyle questionnaire collection will occur, and blood and/or
cerebrospinal fluid (CSF) specimens will be collected for the research assays. I
If one is eligible and agrees to participate in the longitudinal sub-study, they will be
asked to come into the clinic for an Initial Study Visit, and then return every year or every
other year, depending on which group they fit into (Cognitively Normal (CN), Mild Cognitive
Impairment (MCI), Alzheimer's Disease (AD), other neurodegenerative disease) for ongoing
Follow-Up Clinic Visits.
CN participants will come into the clinic every other year, with telephone checks occurring
on alternating years, until the study ends.
MCI, AD, and other participants with a diagnosis of any other neurodegenerative disease will
come into the clinic every year until the study ends.
Those in the Cognitively Normal group, will also partake in a short Telephone Visit on the
year that they do not come into the clinic. This phone call will be done only to
assess/update your medical history and medications.
Genetic testing will take place. No clinical laboratory testing will be done and no results
will be communicated to subjects. Those who are deemed to be cognitively normal, assessed by
cognitive status instruments, will be asked to return to the clinic for ongoing study visits
every other year, with telephone visits on the off year. Those who have a diagnosis of MCI,
AD, or any other neurodegenerative disease will be asked to return to the clinic yearly for
their longitudinal follow-up study visits.
For both the main and longitudinal sub-study, specimens will be banked for future use and can
be provided to other researchers at Georgetown University, other institutions or commercial
enterprise in a de-identified manner through a formal request system. For all investigators,
not affiliated with the Memory Disorders Program, a formal request will be submitted to the
PI for review. If the request is approved, requested specimens and/or data from the study
will be sent in a de-identified manner to ensure date security and privacy. The reason for
the option of data sharing is to enhance exploration of different lines of analysis, and
assist emerging investigators with access to a database with robust data and specimen
collections.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |